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Nitroheterocyclic compounds are widely used as therapeutic agents against a variety of protozoan and bacterial infections.
However, the literature on these compounds, suspected of being carcinogens, is widely controversial. In this study, cytotoxic
and genotoxic potential of three drugs, Nifurtimox (NFX), Benznidazole (BNZ), and Metronidazole (MTZ) was re-evaluated
by diﬀerent assays. Only NFX reduces survival rate in actively proliferating cells. The compounds are more active for base-pair
substitution than frameshift induction in Salmonella; NFX and BNZ are more mutagenic than MTZ; they are widely dependent
from nitroreduction whereas microsomal fraction S9 weakly aﬀects the mutagenic potential. Comet assay detects BNZ- and NFX-
induced DNA damage at doses in the range of therapeutically treated patient plasma concentration; BNZ seems to mainly act
through ROS generation whereas a dose-dependent mechanism of DNA damaging is suggested for NFX. The lack of eﬀects on
mammalian cells for MTZ is conﬁrmed also in MN assay whereas MN induction is observed for NFX and BNZ. The eﬀects of
MTZ, that shows comparatively low reduction potential, seem to be strictly dependent on anaerobic/hypoxic conditions. Both
NFX and BNZ may not only lead to cellular damage of the infective agent but also interact with the DNA of mammalian cells.
Copyright © 2009 Annamaria Buschini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The introduction of nitro-substituted heterocyclic drugs,
such as nitroimidazoles and nitrofurans, heralded a new era.
5-Nitrofurans and 2- and 5-nitroimidazoles are the classes
of nitroheterocyclic drugs most used in the treatment of
infections caused by anaerobic bacteria and a range of
pathogenic protozoan parasites [1–4].
Nitrofuran derivatives do not interact with DNA per
se, but they require metabolic conversion for exerting their
action [5, 6]. These compounds are metabolically activated
to the corresponding hydroxylamines through the reduction
of their functional nitro group [7].
Nifurtimox (NFX, N-(3-methyl-1,1-dioxo-1,4-thiazi-
nan-4-yl)-1-(5-nitro-2-furyl) methane-mine, CAS number
23256-30-6) is a 5-nitrofuran for the treatment of Chagas’
disease (American trypanosomiasis), which aﬀects more
than 10 million people in Central and South America.
Controversial results are reported for NFX in the treatment
in the second stage of African sleeping sickness [8–10].
One possible mechanism of action of NFX as trypanocidal
involves the ability of this agent to form a nitro-anion
radical metabolite, which reacts with the nucleic acids of
the parasite, causing a signiﬁcant breakage in the DNA
[4], and the other involves the production of superoxide
anions and hence hydrogen peroxide [4, 11]. The drug
exhibits particularly serious toxic side eﬀects on patients
[12, 13] generally attributed to NFX nitroreductive
biotransformation to a nitroanion radical, redox cycling,
generation of reactive oxygen species or lipid peroxidation2 Journal of Parasitology Research
[14, 15], production of peroxinitrite radicals [16], and other
nitrite-formingprocesses[17].InductionofmutantsbyNFX
[18–24], but not by its in vivo metabolites [25], was found in
bacterialsystems.ItexhibitedgenotoxiceﬀectsonDrosophila
melanogaster [26], and it caused chromosomal aberrations
(CA), micronucleus (MN) ,and sister-chromatid exchange
(SCE) formation [27–29]. NFX was found to increase cancer
incidence [30, 31] but did not exhibit initiating carcinogenic
activities [32].
Nitroimidazol derivatives are reported to exert their
therapeutic eﬀect through nitrogroup reduction [2, 3].
Antibacterial and antiprotozoal activity appears to result
from the formation of short-lived protonated one-electron
nitro radical anions and other compounds, including nitroso
and hydroxylamine derivatives [3] following reduction of
the nitrogroup by nitroreductases present in the bacterial
or protozoal cell. This intermediate species interacts with
DNA, causing strand breaks with helix destabilization, this
preventing DNA synthesis and, thereby, causing cell death in
both bacteria and protozoal parasites [33, 34].
The 2-nitroimidazol benznidazole (BNZ, N-benzyl-2-
(2-nitroimidazol-1-yl)acetamide, CAS number 22994-85-0)
is the only etiological treatment commercially available for
Chagas disease in many countries from Latin America. This
drug appears to inhibit protein and ribonucleic acid (RNA)
synthesis in the parasite. As NFX, BNZ induces serious toxic
side eﬀects [12]. Several free radical species similar to those
produced by NFX were thought to be involved [4, 14]. It is
mutagenic for Salmonella typhimurium [19, 20, 22, 33–36]a s
wellastheurine and blood oftreatedanimals [25].Itsclasto-
genic ability is controversial since both positive [27, 28, 37–
43] and negative [44] ﬁndings are reported. Carcinogenicity
bioassays reported cancer induction [30, 31].
The 2-nitroimidazol metronidazole (MTZ, 2-(2-methyl-
5-nitro-1H-imidazol-1-yl)ethanol, CAS number 443-48-1)
possesses direct trichomonacidal and amebacidal activity
and shows clinical activity against most obligate anaerobes
[1, 45] .T h ed r u gi sa c t i v ew h e nr e d u c e du n d e rs t r o n g l y
reducing conditions [46] through electron donation from
ferredoxin or ﬂavodoxin, oxidoreductase [47], and possibly
forming an hydroxylamine [48]. Presumably, free radicals
are formed which, in turn, react with cellular components
resulting in death of the microorganism as also supported by
some ﬁndings on the protective role of antioxidants against
MTZ [49]. However, scavenging activities of MTZ on free
oxygen radicals were reported [50–52]. It has been also
suggested that the reactive species are intermediates in the
reductive metabolism of MTZ, which leads to the formation
of acetamide [53]. Mutagenic activity, induced by the drug
[22] as well as by the urine of therapeutically treated patients
[54, 55], was found in bacterial systems. In mammalian cells,
some studies [33, 34, 56–65] indicate that MTZ causes a
loss of DNA helix content, strand breakage, unscheduled
DNA synthesis, and SCEs, whereas others [66–72]d on o t
conﬁrm its genotoxicity. In some in vivo studies, MTZ was
found genotoxic [73, 74]. In many others [68, 71, 75–79]
these eﬀects were not registered. Some data [80] cannot
be clearly interpreted. Some positive eﬀects [57, 66]h a v e
been discussed [81] as to be the result of an infection of
the cells with mycoplasms. According to the International
AgencyforResearchonCancer[82],theevidenceissuﬃcient
to consider MTZ as an animal carcinogen [83–87]b u t
insuﬃciently for humans [88].
For chemotherapy of Chagas’ disease, NFX and BNZ
display most eﬃcacy against the extracellular forms of T.
cruzi during the acute phase of the infection, whereas both
drugs are considered to be, at best, only partially beneﬁcial
againsttheintracellularformthatcauseschronicdisease[89–
94]. Furthermore, the severe side eﬀects of both drugs limit
their use [12, 13,92–94]. MTZ is currently the drug of choice
for treating invasive amoebiasis, but it may not be suﬃcient
to eliminate parasite cysts in the intestine. Moreover, some
unpleasant adverse eﬀects associated with metronidazole
in some patients, and the possibility of parasite resistance
to metronidazole has to be considered [95]. Treatment
of patients with Clostridium diﬃcile infection with MTZ
generally reduces morbidity and mortality, although the
number of patients that do not respond is increasing [96–
98]. There are insuﬃcient data to recommend the use of
metronidazole in persistent diarrhoea of unknown cause or
nonspeciﬁc cause [99]. Furthermore, these compounds were
suspectedofbeingmutagensandcarcinogens[3,4,7,15,27–
29, 31, 33, 34, 94, 100].
Theliteratureonthesewidelyuseddrugsiscontroversial.
To come to a more clear statement with respect to the
modeofactionwere-evaluatedtheirgenotoxicandcytotoxic
potential with diﬀerent in vitro test, that is, Salmonella
reverse mutation assay [101], comet assay [102], micronu-
cleus assay [103, 104], and short- and long-term cytotoxicity
assays.
2.MaterialsandMethods
2.1.Chemicals. Reagentsforelectrophoresis,normalmelting
point and low melting point agarose, dimethyl sulfoxide
(DMSO), ethidium bromide (EtBr), 5-carboxyﬂuorescein
diacetate (FDA), Hoechst 33342 (HO), ethyl methane
sulfonate (EMS), hycantone (HYC), 2-aminoﬂuorene (2-
AF), cell culture medium, buﬀers, and general laboratory
chemicals were from Sigma (Sigma-Aldrich Company Ltd.,
Milan, Italy). Lyophilized postmitochondrial supernatant
rat liver fraction S9 was from MOLTOX INC. (Boone,
NC, USA); Bleomycin from Rhˆ one-Poulenc Rorer (Col-
legeville, PE, USA); Furylfuramide (2-(2-furyl)-3-(5-nitro-
2-furyl)acrylamide) from Wako Pure Chemical Industries
(Osaka, Japan). Nifurtimox (Bayer 2502, Lampit) was from
Bayer. Benznidazole (Rochagan) was from Roche Brasil (Rio
de Janeiro, Brazil). Metronidazole was from Fluka Sigma-
Aldrich(Buchs,Swiss)andBieﬀeM editalSP A(G r osott o ,SO ,
Italy).
2.2. Salmonella/Microsome Test. The bacteria reverse muta-
tion assay [101]o nd i ﬀerent his-Salmonella typhimurium
strains was used to evaluate the mutagenic properties of
the compounds. TA100 strain is predominantly sensitive to
base pair substitution mutagens whereas TA98 is sensitive
to frameshift mutagens. The strains are deﬁcient in excision
repair (uvrB mutation) and contain the plasmid pKM101,Journal of Parasitology Research 3
which activates an error prone DNA repair system, making
them more responsive to a variety of mutagens. The test
was performed in the absence or in the presence of exoge-
nous metabolic activation system (Aroclor 1254-induced
rat liver S9, prepared from adult Sprague Dawley rats, is
supplementedwithdiﬀerentcofactors(glucose-6-phosphate,
NADP-Na2) to a ﬁnal protein concentration of 2mg/mL
incubation) to detect indirect and direct mutagenic activity.
Compounds having a nitro function attached to an
aromatic or heteroaromatic moiety constitute a group of
chemicalsbiologicallyactive.Thereactiveformsaremetabol-
ically generated through nitroreduction and, in many cases,
through oxidative pathways: whereas the oxidative pathways
depend on the presence of the cytochrome P450 family
of enzymes and occur, therefore, mainly in the liver,
nitroreduction is mainly found in bacterial cells [91]. This
may explain why nitro compounds are generally strong
mutagens in the Salmonella mutagenicity assay, whereas
mutagenicity in mammalian cells is not always found for
Salmonella-positive nitro compounds [105]. In this context,
the standard plate incorporation procedure for detecting
his+ revertants was integrated by nitroreductase deﬁcient
strains to better understand compound mechanisms. These
bacteria, TA98NR and TA100NR strains, are lacking the
“classical” nitroreductase and were isolated as niridazole
resistant derivatives of TA98 and TA100 strains, respectively
[106, 107].
The results of the Salmonella assays are given as mean
number of revertants from three independent plates (±SD).
ThedatawereanalysedbyusingSPSS11(SPSSInc.,Chicago,
IL, USA) statistical package. A one-way analysis of the
variancetestwasperformed.IfasigniﬁcantF value(P ≤ .05)
was obtained, the comparison between controls and treated
samples was analysed by using Dunnett’s C-test. A positive
result was deﬁned as a reproducible dose-related increase in
the number of his+ revertants. Least squares linear regression
analysis was used to calculate speciﬁc activity. The activity
of the S9 mix and the responsiveness of the tester strains
were veriﬁed by including appropriate controls into each
experiment. Speciﬁcally, DMSO (80μL/plate), used to redis-
solve the compounds, was identiﬁed as the negative control
whereas hycantone (HYC, 75μg/plate) and 2-aminoﬂuorene
(2-AF, 2.5μg/plate) were used as positive controls without
and with S9 mix, respectively [108] .I no r d e rt oc h a r a c t e r i z e
the mutagenic response of NR strains with respect to
the parental strains, we examined their sensitivity to 2-
nitroﬂuorene (2-NF, 15μg/plate) and furylfuramide (FYFA,
20ng/plate), whose mutagenicity is substantially lower in
nitroreductase deﬁcient than in nitroreductase proﬁcient
strains [109].
2.3. Cytotoxicity Assays in Human Cells
Short-Term Exposure. Heparin-anticoagulated peripheral
blood was obtained by venipuncture from consenting
healthy nonsmoker donors as provided by the AVIS (Italian
Association of Voluntary Blood Donors). In order to isolate
the leukocytes, the blood was maintained at 37◦Cf o r
5 minuets in an erylysis buﬀer (155mM NH4Cl, 5mM
KHCO3, 0.005mM Na2EDTA, pH 7.4), centrifuged and
washedwithPBS,andﬁnallyresuspended(∼106 cells/mL)in
RPMI-1640 medium (Gibco). Appropriate amounts of the
compounds were added to an Eppendorf tube containing the
cell suspension (106 cells). The cells were treated for 1 hour
at 37◦ and then washed twice in PBS. Toxicity was checked
immediatelyaftertheexposure.Cellsurvivalwasdetermined
by the carboxyﬂuorescein diacetate/ethidium bromide-assay
added with Hoechst 33342 (HO). A freshly staining solution
(15μg/mL carboxyﬂuorescein diacetate, 2.5μg/mL ethidium
bromide, 2μg/mL HO in PBS) was prepared. 500μlo fc e l l
suspension (equivalent to about 5 × 105 cells) was mixed
with 10μL of the staining solution, maintained at 37◦Cf o r
5 minuets. The cells were counted (200 cells per data point)
under a ﬂuorescent microscope (DAPI/FITC ﬁlters): viable
leukocytes, whose nucleus is blue-stained by Hoechst 33342,
develop a cytoplasmic green ﬂuorescence, while dead cells
accumulate ethidium bromide to develop orange ﬂuorescent
DNA.
Long-Term Exposure. Immortalized lymphocytes, that is,
peripheral blood cells transformed by Epstein-Barr virus in
a lymphoblastoid cell line able to actively proliferate (kindly
provided by Dr. Dolcetti, (Centro di Riferimento Onco-
logico, CRO Aviano, Italy), were used for this assay. The cells
(2 × 105 cell/mL were incubated at 37◦Ci na na t m o s p h e r e
containing 5% CO2 during 48 hours in a 96-well plate in
the presence of diﬀerent concentrations of the drug. At the
end of the exposure period, cellular suspension was added
with the solution reagent (20μL) of CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega, Madison, WI,
USA). After 4 hours incubation, the absorbance at 490nm
was recorded with a 96-well plate reader (MULTISKAN
EX, Thermo Electron Corporation, Vantaa, Finland). The
quantityofformazanproductasmeasuredbytheabsorbance
at 490nm was directly proportional to the number of living
cells in culture [110, 111].
2.4. Comet Assay
2.4.1. Alkaline Assay. The Comet assay was performed,
basically according to Singh and coll [102] with minor
modiﬁcations, on fresh human leukocytes treated as previ-
ouslydescribedforshort-termcytoxicityassay(1hour,37◦C)
[112]. Cell lysis was carried out at 4◦C overnight by exposing
cells to a buﬀer containing 2.5M NaCl, 10mM Na2EDTA,
10mM Tris-HCl, 1% Triton X-100, and 10% DMSO, pH
10. DNA unwinding was achieved over 20 minutes in an
electrophoretic alkaline buﬀer (1mM Na2EDTA, 300mM
NaOH, 0◦C, pH > 13); electrophoresis was then carried
out for 20 minutes (0.78V/cm, 300mA) at 0◦C in the same
buﬀer, followed by neutralisation in 0.4M Tris-HCl, pH 7.5.
DNA was stained with 100μL ethidium bromide (2μg/mL)
before the examination at 400x magniﬁcation under a Leika
DMLB ﬂuorescence microscope (excitation ﬁlter BP 515–
560nm, barrier ﬁlter LP 580nm) using an automatic image
analysis system (Release 2.1–Sarin, Florence, Italy). The
migration distance between the edge of the comet head and
end of the tail (total length, TL) provided representative data4 Journal of Parasitology Research
on genotoxic eﬀects. The samples were coded and evaluated
blind (50cellspereachoftworeplicateslidesperdata point).
All of the tests were performed at least three times. Ethyl
methane sulfonate (2mM) was used as positive control (TL
= 61.03 ± 4.73μm).
2.4.2. Modiﬁed Comet Assay for Detection of Oxidised Bases.
By using endonuclease III (ENDOIII), a DNA glycosy-
lase/endonuclease able to recognise and cleave classes of
lesions, speciﬁc DNA base modiﬁcations such as oxidised
pyrimidine bases are converted to strand breaks. These
strand breaks can be detected by the comet assay as
previously reported. Oxidatively generated damage can
be evaluated easily by comparing the DNA migration in
enzyme-or buﬀer-treated samples. The comet assay, with the
modiﬁcation of an extra step after lysis in which DNA is
digested with the repair enzyme, was performed according
to Collins et al. [113]. Brieﬂy, after cell lysis, the slides
were washed three times with the enzyme buﬀer (0.1M
KCl,0.5mMNa2EDTA,40mMHEPES(4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid), 0.2mg/mL bovine serum
albumin, pH 8 with KOH) and incubated with ENDOIII in
this buﬀer (or in buﬀer alone). Hydrogen peroxide (50μM)
was used as a positive control (TL = 47.13 ± 2.09μm).
ENDOIII was isolated from bacteria containing over-
producing plasmids (Collin’s Laboratory, Rowett Research
Institute, Bucksburn, Aberdeen, UK). The enzyme-treated
gels reveal alkali labile sites and strand breaks (ALS/SB)
and oxidised bases (ALS/SB + OX). Assuming a linear dose
response,subtractionof(ALS/SB)from(ALS/SB+OX)gives
a measure of oxidised bases.
The SPSS 11 statistical package was used to analyse
statistical diﬀerences between samples. Statistical diﬀerences
between controls and treated samples were ﬁrst determined
with the nonparametric Wilcoxon rank-sum test for each
experiment. The mean values from the repeated experiments
were used in a one-way analysis of variance. Analysis of
variance was followed by single or multiple pairwise com-
parisons. Data were tested for normality and homogeneity
of variance. When these criteria were met, the data were
compared using Dunnett’s version of the t-test.
2.5. Micronucleus (MN) Assay. The MN assay was per-
formed using blood samples from healthy, nonsmoking
males, as provided by the AVIS (Italian Association of
Voluntary Blood Donors). Lymphocytes were separated by
Lymphoprep density gradient (Axis-Shield PoC As, Oslo,
Norway) and, after two washes in RPMI 1640 medium,
cultured at a concentration of 5 × 105 cells/mL in RPMI
1640 containing 15% fetal calf serum (FCS), 2% v/v Kary-
oMAX phytohemoagglutinin (Invitrogen LTD, Collegeville,
PE, USA), 2mM L-glutamine, 25IU/mL penicillin, and
25μg/mL streptomycin. The cultures were incubated at
37◦C in an atmosphere containing 5% CO2 for 72 hours.
Cytochalasin-B was added 44 hours after the start of
incubation at a ﬁnal concentration of 6μg/mL; at 48 hours,
the lymphocytes were treated with the diﬀerent drugs. Sterile
DMSO (1.6μl/ml) was used as a solvent control, and the
positive controls were bleomycin (6μg/ml), ethyl methane
Table 1: Speciﬁc mutagenic activity (revertant increase/dose unit
calculated by linear regression analysis on the curve section with
response linearity) of NFX, BNZ, and MTZ on diﬀerent Salmonella
strainswithoutorwith(+)S9mix;inbrackets:r2 value(A).Positive
controls are reported for each strain (HYC: hycantone; 2-AF: 2-
aminoﬂuorene; FYFA: furylfuramide; 2NF: 2-nitroﬂuorene); mean
(±SD) of three plates (B). ∗P < .05 Dunnett’s C.
(a)
Revertant increase/dose unit
Strain NFX BNZ MTZ
TA100 80.28 (0.99) 64.96 (0.98) 5.11 (0.98)
TA100 + 78.91 (0.98) 60.92 (0.98) 5.45 (0.96)
TA100NR 5.18 (0.99) 1.75 (0.81) 0.37 (0.94)
TA98 2.37 (0.99) 0.07 (0.88) 0.05 (0.89)
TA98 + 2.06 (0.99) 0.10 (0.93) 0.08 (0.97)
TA98NR 0.17 (0.94) 0.07 (0.93) 0.02 (0.79)
(b)
Revertant/plate
Strain HYC 2-AF FYFA 2-NF
TA100 968 ± 103∗ 194 ± 21 1133 ± 70∗
TA100 + 521 ± 47∗
TA100NR 785 ± 97∗ 247 ± 34
TA98 870 ± 90∗ 21 ± 5 189 ± 16∗ 169 ± 7∗
TA98 + 808 ± 70∗
TA98NR 833 ± 71∗ 25 ± 41 9 ± 4
sulfonate (120μg/ml), and demecolcine (0.5μg/ml). Each
treatment was tested with cells from two donors, performed
in duplicate separate cultures (i.e., four cultures were set
up for each treatment). After incubation, the lymphocytes
were collected and resuspended in a mild hypotonic solution
(0.075M KCl) and then added with an ice-cold 5 : 3
acetic acid:methanol solution. After centrifugation (500g,
10 min), the pellets were resuspended in cold (−20◦C)
methanol and maintained at −20◦C (at least 24 hours). The
cells were 2 fold washed (7 : 1 methanol:acetic acid, −20◦C),
plated on cold degreased slides, air-dried, and then stained
with 2% v/v Giemsa (Carlo Erba, Milano, Italy). Scoring
was done using an Exacta-Optech (Munich, Germany) light
microscopeat1000Xmagniﬁcation.Micronucleiwerescored
according to the criteria described by Fenech [103, 104].
At each dose, at least 1000 binucleated (BN) lymphocytes
for each culture were examined for the presence of one
or more micronuclei. The MN frequency in 1000 BN cells
was then calculated for each treatment. Assays with too
few BN cells to determine the MN frequency (due to
extensive cytotoxic eﬀects) were classiﬁed as “toxic.” Cell-
cycle parameters were evaluated by classifying 1000 cells
according to the number of nuclei. 1000 cells were counted
and scored as mononucleated, binucleated, trinucleated, or
tetranucleated and the percentages of the diﬀerent types of
cells were calculated. The nuclear division index (NDI) was
calculated by the formula, NDI = ( M 1+2 M 2+3 M 3+
4M4)/N, where M1 through M4 indicate the number of cellsJournal of Parasitology Research 5
with 1/4 nuclei, and N indicates the total number of cells
scored [114].
The statistical analysis of MN frequency was performed
using the 2χ-test. NDI data were analyzed by Student’s t-test.
3. Results
3.1. Salmonella Plate Incorporation Test. The compounds
were investigated on diﬀerent strains (TA100, TA100NR,
TA98, TA98NR) with/without microsomal rat liver fraction
( S 9 m i x ) .T h ec o m p o u n d sa r em o r ea c t i v ef o rb a s e - p a i r
substitution (TA100) than frame-shift induction (TA98).
Mutant induction is poorly aﬀected by S9 metabolic acti-
vation whereas the nitroreduction process is an essen-
tial requirement in order to induce mutagenic eﬀects on
Salmonella. On TA100 strain, NFX and BNZ seem to have a
similarspeciﬁcactivity(Table 1).MTZsigniﬁcantlyincreases
the revertant number only at concentrations higher than
NFX- and BNZ-eﬀective ones (see Table1 in Supplementary
Materialavalibleonline atdoi:10.1155/2009/463575) andits
speciﬁc activity is more than ten times lower than NFX and
BNZ (Table 1). NFX is the most active on TA98 strain, which
shows a low sensitivity against BNZ and MTZ.
3.2. Human Cells
3.2.1. Cytotoxicity Assays
Short-Term Exposure. For all the compounds, the cellular
survival rate did not appear to be aﬀected by the 1hours-
treatment in the range of doses used (NFX: 0–348μM; BNZ:
0–348μM; MTZ: 0–585μM) when measured immediately
after the exposure (data not reported).
Long-Term Exposure. The assay on cultured lymphocytes
treated for 48 hours (Figure 1) did not show any signiﬁcant
eﬀects induced by BNZ and MTZ whereas a signiﬁcant
decrease of cell population (P<. 05) was observed for NFX
at concentration ≥ 56μM. These cells need a 48-hour period
for doubling their number. In this context, for evaluating if
NFX cytotoxic eﬀect was cell-cycle dependent, the cellular
survival was also evaluated after a shorter exposure time
(24hours). In this case, no cytotoxic eﬀect was induced (see
Figure1 in Supplementary Material).
3.2.2. Genotoxicity Assays
Comet Assay. The data relative to the primary DNA damage
detected on human leukocytes after 1-hours treatment by
the comet assay performed at pH > 13 (Figure 2(a)) show
strong diﬀerences among the three drug eﬀectiveness. To
improve our understanding on the drug action mechanism,
we proceeded to speciﬁcally measure BNZ- and NFX-
induced oxidative DNA damage by using bacterial repair
endonuclease III in the modiﬁed comet assay protocol [113]
(Figure 2(b)).
BNZ DNA damaging activity was mainly linked to
oxidative stress whereas NFX induced DNA base oxidation
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Figure 1: Cytotoxic eﬀects induced in immortalized lymphocytes
when detected by MTS assay (48 hours treatment).
Table 2: Speciﬁc genotoxic activity of NFZ, BNZ, or MTZ on
human leukocytes. I: alkaline comet assay; II: comet assay modiﬁed
with ENDOIII for DNA oxidative damage.
DNA migration/dose unit (μm/μM)
Drug I II
NFX 0.0369 (r2 = 0.8043) 0.106 (r2 = 0.9732)
BNZ 0.3357 (r2 = 0.941) 0.9077 (r2 = 0.8351)
MTZ 0.0004 (r2 = 0.017)
only at doses ≥ 87 μM. These ﬁndings suggest that NFX
could act by a dose-dependent mechanisms: at lower doses, a
DNAdamagebasicallyindependentfromtheoxidativestress,
that is, DNA migration increase detected by the “classic”
assay, and an oxidation of DNA bases at higher doses. BNZ
speciﬁc activity (Table 2) in inducing DNA oxidative damage
was about tenfold higher than that of NFX.
MNAssay. On24-hourstreatedlymphocytes,thenitrofuran
NFX was able to induce a signiﬁcant increase (P<. 05)
of MN (Table 3) whereas the two nitroimidazoles (BNZ
and MTZ) did not alter MN frequency in the range of
doses used (see Table2in Supplementary Material). NFX
was also the only drug that signiﬁcantly (P<. 05) reduced
nuclear division (Table 3). The percentages of mono-, bi-
, tri-, and tetranucleated cells in NFX-treated lymphocytes
(see Figure2 in Supplementary Material) well represents this
reduction. Since on 24-hours treated lymphocytes, MTZ and
BNZ did not induce any eﬀect, the cells were exposed to the
drugs for a longer time (72 hours) as previously reported
for MTZ [115]. The data (Table 3) show an increase of MN
frequency in cell treated with BNZ, without some decrease6 Journal of Parasitology Research
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Figure 2: DNA damage detected in human leukocytes treated (37◦C, 1 hour) with NFX, BNZ, and MTZ. (a): DNA damage is expressed
as total migration length (TL, μm) detected by the alkaline comet assay. (b) Speciﬁc oxidatively generated damage to DNA detected by the
modiﬁed comet assay (ENDO III). DNA oxidative damage is expressed as DNA migration (μm) increase with respect to the assay without
enzymes. Mean ± SD of three independent experiments. Filled symbols, P<. 05 (Dunnett’s C) with respect to dose 0.
of nuclear division. On the other hand, the treatment with
MTZ did not induce any alteration of both MN and NDI.
4. Discussion and Conclusions
The data obtained in this study on the S. typhimurium muta-
tion assay show that the three drugs are more active for base-
pair substitution than frameshift induction, in agreement
withprevious reports onnitroheterocycle compounds [7,19,
20] and are widely dependent from nitroreductase activity.
As t u d y[ 19] reports that the presence of S9 mix decreased
BNZ and NFX mutagenicity on Salmonella even if these data
were not conﬁrmed [20]. Our data show that microsomal
fraction S9 does not or weakly alter the mutagenicity of the
tested compounds. The three drugs are diﬀerently eﬀective
on Salmonella: NFX and BNZ induce in the TA100 strain a
signiﬁcant revertant increase at the lowest used dose whereas
MTZ signiﬁcantly increases the revertant frequency only at
higher doses.
The data on Salmonella suggest that these drugs act as
direct mutagens, as generally suggested for nitroheterocycle
compounds [7]. On the other hand, nitrogroup reduction
strongly inﬂuences their mutagenic capability. The DNA-
reactive forms of nitro compounds may be metabolically
generated through nitroreduction [4] and, in some cases,
through oxidative pathways [105].
Bacterial mutagenicity assay could give an exaggerated
picture of the potency of nitro compounds relative to
the eﬀects (mutation and tumour induction) observed
in animals [7, 116, 117]. This is probably due to two
factors: ﬁrst, to the greater activity of the nitroreductases
in bacteria compared to mammalian cells, and second, to
the detoxiﬁcation reactions and excretion processes which
occurinanimals.Indeed,thesefactorsproducethediﬀerence
in sensitivity between pathogen and host, which is the
basis for the practical use of nitrocompound derivatives in
clinical and veterinary medicine. This resulted in labelling
the Salmonella mutagenicity assay as ‘not predictive’ for this
class of compounds [7, 116, 117]. The evaluation of the
mutagenic potential of a nitrocompound, therefore, relies
strongly on the outcome of tests conducted in mammalian
systems.
In previous studies [62], MTZ produced signiﬁcant
dose-related increases of DNA damage, when tested on
human lymphocytes in aerobic conditions using the comet
assay. Concerning the mechanisms of action, these authorsJournal of Parasitology Research 7
Table 3: Mean frequency of Micronuclei (MN) in binucleated cells and Nuclear Division Index (NDI) in human lymphocytes treated with
NFX(24hours)orBNZ(72hours)Positivecontrols:-ethylmethanesulfonate(1μM):15.0 ±2.8;bleomycin(4μM):26.0 ±4.0;demecolcine
(0.9μM): 65.0 ± 3.3.
NFX (24 hours) BNZ (72 hours)
Dose NDI NDI MN Dose NDI NDI MN
(µM) (%) (×10−3 BN) (µM) (%) (×10−3 BN)
0 1.97 ± 0.10 100 2.0 ± 0.5 0 1.93 ± 0.10 100 3.5 ± 0.5
1.7 1.95 ± 0.12 99 ± 62 . 5 ± 0.5 1.9 1.97 ± 0.10 102 ± 53 . 0 ± 0.5
3.5 1.97 ± 0.07 100 ± 42 . 0 ± 1.0 3.8 1.93 ± 0.11 100 ± 63 . 5 ± 1.0
7.0 1.89 ± 0.05 96 ± 33 . 0 ± 1.0 7.7 2.00 ± 0.07 104 ± 44 . 0 ± 1.0
13.9 1.85 ± 0.06 94 ± 32 . 5 ± 0.5 15.4 1.98 ± 0.06 102 ± 34 . 0 ± 1.5
27.9 1.75 ± 0.10 89 ± 53 . 0 ± 0.5 30.7 1.99 ± 0.05 103 ± 33 . 5 ± 1.0
55.7 1.69 ± 0.04a 86 ±2a 3.0 ± 1.0 61.5 2.06 ± 0.07 107 ± 43 . 0 ± 0.5
87.0 1.61 ± 0.10a 82 ±5a 4.0 ± 0.5 96.1 2.05 ± 0.03 106 ± 29 . 0 ± 0.5
174.0 1.43 ± 0.03a 73 ±2a 9.0 ± 1.0 192.1 2.00 ± 0.07 104 ± 4 13.0 ± 1.0b
348.1 1.41 ± 0.02a 72 ±1a 12.0 ± 1.0b 384.2 1.93 ± 0.10 100 ± 6 16.5 ± 0.5b
aP<. 05 Student’s t-test; bP<. 052χ-test
proposedthatMTZwasabletoinduceDNAdamagethrough
the so-called futile cycle that is, one electron reduction of the
drug leads to the production of nitroradical anions which
are oxidised in the presence of oxygen and may generate
reactive oxygen species (ROS). On the other hand, in our
experiments, MTZ did not induce any signiﬁcant increase on
DNA migration up to 585μM, that is, about tenfolds higher
(100μg/ml) than plasmatic concentration in MTZ-treated
patients (8–13μg/ml). In actual fact, conﬂicting results
are reported in literature regarding MTZ genotoxicity in
mammal cells [33, 34, 57, 60–66, 68, 71–81]. The lack of any
signiﬁcant cytotoxic or genotoxic eﬀects induced by MTZ
in our experimental conditions on human cells suggests
that MTZ biological activity could be strictly dependent on
anaerobic conditions [81, 118]. In fact, Korbelik and Horvat
[67]observedclastogenic eﬀectsonlyinhypoxic mammalian
cells: in this condition, the toxic eﬀect of a reduction of the
nitro group should be similar to those in microorganisms
living under anaerobic conditions.
Inagreementwithsomepreviousreports[27,28,37–39],
ourﬁndings conﬁrmed thatBNZand NFX are able toinduce
signiﬁcant genotoxic eﬀects on human cells. Furthermore,
the lowest BNZ and NFX doses able to induce DNA damage
detectable by the comet assay are in the range of plasmatic
concentrations in patients therapeutically treated with these
two nitro compounds.
The two drugs are reported to produce similar free rad-
icals [4, 14]. However, in our experimental conditions, the
behaviourofBNZandNFXininducingDNAoxidativedam-
age suggests diﬀerent mechanisms of action for the two com-
pounds. Speciﬁcally, the analysis of DNA oxidative damage
data shows that BNZ mainly acts through free radical species
production whereas dose-depending mechanisms could be
suggested for NFX. Some diﬀerences between the nitrofuran
and the nitroimidazol were also found in MN test: shorter
exposure time is necessary for NFX than for BNZ (24 hours
versus 72 hours) to induce a signiﬁcant genetic damage.
Even cytotoxicity data suggest speciﬁc action mecha-
nisms for the three compounds. Whereas no eﬀect was
observed on the survival of nondividing cells up to the
highest doses used for all the drugs, NFX was able to induce
cytotoxic eﬀects on actively proliferating cells at 56μM.
NFX and BMZ genotoxicity was detected by both comet
and MN assay, even if in diﬀerent ranges of concentrations.
Comet assay showed signiﬁcantly increased DNA damage at
lower concentrations, but these lower concentrations were
not able to increase the chromosomal damage detected by
MN assay. The discrepancies between the results obtained by
the Comet and MN tests, as reported in other investigations
[119, 120], are probably caused by the nature of these two
assays. The Comet detects primary DNA lesions resulting
from the balance of DNA damage and repair mechanisms.
The MN test detects DNA damage that has been trans-
formed to structural and numerical chromosome alterations
and reveals ﬁxed DNA lesions or unrepairable aneugenic
eﬀects.
A distinguishing property among the three compounds
is their reduction potential. The 5-nitroimidazol derivative
(MTZ) shows comparatively low reduction potential: it can
bereducedtothecorrespondingaminoderivativeonlyunder
anaerobic conditions and its spectrum of activity can result
limited to anaerobic or facultative anaerobic bacteria. On
the other hand, both the antitrypanosomal drugs, NFX and
BNZ, may not only lead to cellular damage of the infective
agent but also interact with the DNA of mammalian cells by
the formation of free radicals and redox cycling.
In conclusion, the genotoxic proﬁle of MTZ, NFX, and
BNZ is further deﬁned from our ﬁndings. MTZ therapeutic
use could represent a genotoxic hazard only for the host
cellsinanoxicconditions.ThehighDNAdamagingpotential
of NFX and BNZ on mammalian cells, together with other
known severe side-eﬀects on patients and low eﬀectiveness
in the second stage of the Chagas’ disease, call for new safer
drugs against Trypanosoma infection.8 Journal of Parasitology Research
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